Medtide Sets Board Meeting to Approve 2025 Annual Results and Consider Final Dividend

Medtide, Inc. Class H ( (HK:3880) ) has provided an announcement.

Medtide Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025, and to authorize their public release. At the same meeting, the board will also consider whether to recommend a final dividend to shareholders and attend to other corporate matters, a process that could influence investor expectations on profitability, capital allocation and future shareholder returns.

The announcement, issued under the authority of chairwoman and chief executive officer Dr. Xu Qi, confirms that the company’s governance bodies are preparing for the regular annual results cycle. The inclusion of potential dividend deliberations underscores the board’s focus on balancing business performance with shareholder distribution policies, which may affect Medtide’s positioning in the Hong Kong market and its appeal to income-focused investors.

The most recent analyst rating on (HK:3880) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Medtide, Inc. Class H stock, see the HK:3880 Stock Forecast page.

More about Medtide, Inc. Class H

Medtide Inc. is a joint stock company incorporated in the People’s Republic of China with limited liability and listed on the Stock Exchange of Hong Kong under stock code 3880. The company operates in the medical sector, with a board comprising executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a Hong Kong-listed healthcare-related issuer.

Average Trading Volume: 127,543

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$3.24B

Learn more about 3880 stock on TipRanks’ Stock Analysis page.